Numerous clinical trials evaluate Crizotinib from Phase 1 safety evaluations to Phase 4 post-marketing studies, primarily investigating its efficacy and safety in non-small cell lung cancer harboring ALK or ROS1 alterations, anaplastic large cell lymphoma, papillary renal cell carcinoma, and advanced solid tumors. Sponsored by pharmaceutical companies, biotechnology firms, and academic research institutions, these studies currently span recruitment statuses ranging from actively recruiting and completed to terminated and unknown.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05725200 | RECRUITING | Metastatic Colorectal Cancer |
Oslo University Hospital |
2022-09-27 | PHASE2 |
| NCT02201992 | ACTIVE_NOT_RECRUITING | ALK Gene Rearrangement; ALK Gene Translocation; ALK Positive; Stage IB Non-Small Cell Lung Carcinoma AJCC v7; Stage II Non-Small Cell Lung Cancer AJCC v7; Stage IIA Non-Small Cell Lung Carcinoma AJCC v7; Stage IIB Non-Small Cell Lung Carcinoma AJCC v7; Stage IIIA Non-Small Cell Lung Cancer AJCC v7 |
ECOG-ACRIN Cancer Research Group |
2015-03-23 | PHASE3 |
| NCT07804186 | RECRUITING | Uveal Melanoma |
IDEAYA Biosciences |
2026-09 | PHASE3 |
| NCT07560410 | NOT_YET_RECRUITING | Bone Cancer |
China Medical University Hospital |
2026-05-15 | PHASE1; PHASE2 |
| NCT06564324 | RECRUITING | Non Small Cell Lung Cancer |
Nuvation Bio Inc. |
2024-11-27 | PHASE3 |
| NCT05160922 | ACTIVE_NOT_RECRUITING | NSCLC; ALCL; IMT |
Pfizer |
2021-12-27 | PHASE4 |
| NCT04693468 | RECRUITING | Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Recurrent Malignant Solid Neoplasm |
M.D. Anderson Cancer Center |
2020-12-01 | PHASE1 |
| NCT06563999 | RECRUITING | Lung Cancer Stage III; Mutation |
Sun Yat-sen University |
2024-11-01 | PHASE2 |
| NCT02925234 | RECRUITING | Cancer; Tumors; Neoplasm; Neoplasia |
The Netherlands Cancer Institute |
2016-08 | PHASE2 |
| NCT03947385 | RECRUITING | Metastatic Uveal Melanoma; Cutaneous Melanoma; Colorectal Cancer; Other Solid Tumors |
IDEAYA Biosciences |
2019-06-28 | PHASE1; PHASE2 |
| NCT05987332 | ACTIVE_NOT_RECRUITING | Metastatic Uveal Melanoma |
IDEAYA Biosciences |
2023-10-31 | PHASE2; PHASE3 |
| NCT02465060 | ACTIVE_NOT_RECRUITING | Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Exocrine Pancreas Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm; Kidney Carcinoma; Liver Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Corpus Neoplasm; Malignant Uterine Neoplasm; Melanoma; Multiple Myeloma; Ovarian Carcinoma; Prostate Carcinoma; Rectal Carcinoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Colon Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Glioma; Recurrent Head and Neck Carcinoma; Recurrent Liver Carcinoma; Recurrent Lung Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Malignant Uterine Corpus Neoplasm; Recurrent Melanoma; Recurrent Multiple Myeloma; Recurrent Ovarian Carcinoma; Recurrent Pancreatic Carcinoma; Recurrent Prostate Carcinoma; Recurrent Rectal Carcinoma; Recurrent Skin Carcinoma; Recurrent Thyroid Gland Carcinoma; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma; Skin Carcinoma; Thyroid Gland Carcinoma |
National Cancer Institute (NCI) |
2015-08-17 | PHASE2 |
| NCT03297606 | RECRUITING | Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors |
Canadian Cancer Trials Group |
2018-03-23 | PHASE2 |
| NCT04322890 | RECRUITING | Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation; ROS1 Gene Mutation; MET Gene Mutation |
Hunan Province Tumor Hospital |
2020-04-16 | PHASE2 |
| NCT04603807 | ACTIVE_NOT_RECRUITING | Carcinoma, Non-Small-Cell Lung |
Hoffmann-La Roche |
2021-09-30 | PHASE3 |
| NCT02194738 | ACTIVE_NOT_RECRUITING | Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Cancer AJCC v8; Stage IIB Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIA Lung Non-Small Cell Cancer AJCC v7; Stage IIIB Lung Cancer AJCC v8 |
National Cancer Institute (NCI) |
2014-09-26 | |
| NCT04423185 | RECRUITING | Rare Tumor |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2020-08-15 | PHASE2 |
| NCT05014464 | RECRUITING | Non-small Cell Lung Cancer |
Hunan Province Tumor Hospital |
2021-11-13 | PHASE2 |
| NCT06254599 | NOT_YET_RECRUITING | Non-small Cell Lung Cancer |
Shouyao Holdings (Beijing) Co. LTD |
2024-05-01 | PHASE3 |
| NCT06082635 | ACTIVE_NOT_RECRUITING | Non Small Cell Lung Cancer |
Shenzhen TargetRx Co., Ltd. |
2023-12-14 | PHASE3 |
| NCT06140836 | ACTIVE_NOT_RECRUITING | Carcinoma, Non-Small-Cell Lung |
Bristol-Myers Squibb |
2023-12-21 | PHASE3 |
| NCT02767804 | ACTIVE_NOT_RECRUITING | Non-small Cell Lung Cancer |
Xcovery Holdings, Inc. |
2016-06 | PHASE3 |
| NCT03194893 | COMPLETED | Neoplasms |
Hoffmann-La Roche |
2017-07-05 | PHASE3 |
| NCT06569420 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer; ALK-positive; SAF-189s |
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. |
2021-12-31 | PHASE3 |
| NCT04030429 | TERMINATED | Endometrial Cancer Recurrent |
National Cheng-Kung University Hospital |
2019-09-01 | PHASE2 |
| NCT05204628 | UNKNOWN | Non-small Cell Lung Cancer |
Xuanzhu Biopharmaceutical Co., Ltd. |
2022-02-07 | PHASE3 |
| NCT04322578 | UNKNOWN | Non-small Cell Lung Cancer |
Hunan Province Tumor Hospital |
2020-03-24 | PHASE2 |
| NCT04283669 | COMPLETED | Neurofibromatosis 2; Progressive Vestibular Schwannoma (VS) |
University of Alabama at Birmingham |
2020-02-18 | PHASE2 |
| NCT04084717 | COMPLETED | Non-squamous Non-small-cell Lung Cancer; Stage IV Non-small Cell Lung Cancer; ROS1 Gene Rearrangement; MET Activating Mutation; MET Amplification |
University Health Network, Toronto |
2019-12-03 | PHASE2 |
| NCT04632758 | UNKNOWN | Non-small Cell Lung Cancer |
Qilu Pharmaceutical Co., Ltd. |
2019-06-01 | PHASE3 |
| NCT03620643 | COMPLETED | Lobular Breast Carcinoma; Gastric Cancer; Triple Negative Breast Cancer; CDH1 Gene Mutation |
Royal Marsden NHS Foundation Trust |
2019-05-09 | PHASE2 |
| NCT06062810 | Not yet recruiting | Non-Small Cell Lung Cancer |
Han Xu M.D. Ph.D. FAPCR Sponsor-Investigator IRB Chair|Medicine Invention Design Inc |
2024-03-28 | Phase 2|Phase 3 |
| NCT03596866 | COMPLETED | ALK+ Advanced NSCLC |
Takeda |
2019-04-19 | PHASE3 |
| NCT05297890 | ACTIVE_NOT_RECRUITING | Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer |
CStone Pharmaceuticals |
2022-05-27 | PHASE2 |
| NCT02664935 | COMPLETED | Non-Small Cell Lung Cancer; Carcinoma, Squamous Cell; Adenocarcinoma |
University of Birmingham |
2015-05-13 | PHASE2 |
| NCT02761057 | COMPLETED | Locally Advanced Papillary Renal Cell Carcinoma; Metastatic Papillary Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma |
National Cancer Institute (NCI) |
2016-07-25 | PHASE2 |
| NCT03672643 | TERMINATED | ALK or ROS1-positive NSCLC |
Pfizer |
2019-01-28 | PHASE4 |
| NCT01121588 | TERMINATED | Neoplasms Malignant |
Pfizer |
2011-03-22 | PHASE1 |
| NCT00828919 | COMPLETED | Solid Tumors |
Pfizer |
2003-03-07 | |
| NCT03574402 | UNKNOWN | Carcinoma, Non-Small-Cell Lung |
Guangdong Association of Clinical Trials |
2018-07-09 | PHASE2 |
| NCT04292119 | UNKNOWN | Lung Cancer; Anaplastic Lymphoma Kinase Gene Translocation; ROS1 Rearrangement; Relapsed Cancer; MET Amplification; Resistant Cancer; NSCLC |
Massachusetts General Hospital |
2020-05-01 | PHASE1; PHASE2 |
| NCT02419287 | COMPLETED | Anaplastic Large Cell Lymphoma, ALK-Positive |
University of Milano Bicocca |
2015-04 | PHASE2 |
| NCT06357975 | ACTIVE_NOT_RECRUITING | Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma |
National Cancer Institute (NCI) |
2016-07-29 | PHASE2 |
| NCT06360575 | ACTIVE_NOT_RECRUITING | Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma |
National Cancer Institute (NCI) |
2016-07-20 | PHASE2 |
| NCT03607188 | COMPLETED | Non-small Cell Lung Cancer |
Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
2018-10-18 | PHASE1 |
| NCT04211922 | TERMINATED | ALK-positive Non-small Cell Lung Cancer |
Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
2020-01-21 | PHASE2 |
| NCT03439215 | UNKNOWN | Carcinoma, Non-Small-Cell Lung |
Fondazione Ricerca Traslazionale |
2017-06-13 | PHASE2 |
| NCT05792644 | COMPLETED | ALK Phosphorylation |
Harbin Medical University |
2018-01-01 | |
| NCT04856293 | COMPLETED | Healthy Participants |
Pfizer |
2021-04-16 | PHASE1 |
| NCT02638428 | UNKNOWN | Relapsed Pediatric Solid Tumor; Refractory Pediatric Solid Tumor; Relapsed Pediatric AML; Refractory Pediatric AML |
Samsung Medical Center |
2015-12 | PHASE2 |
| NCT04009317 | UNKNOWN | ALK-positive NSCLC |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2019-08-13 | PHASE3 |
| NCT04056572 | UNKNOWN | ALK-positive NSCLC |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2019-08-13 | PHASE2 |
| NCT01548144 | TERMINATED | Advanced Cancers |
M.D. Anderson Cancer Center |
2012-04 | PHASE1 |
| NCT03737994 | TERMINATED | Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8 |
National Cancer Institute (NCI) |
2019-07-25 | PHASE2 |
| NCT02277457 | WITHDRAWN | Non-Small Cell Lung Cancer |
University of Michigan Rogel Cancer Center |
2015-09 | EARLY_PHASE1 |
| NCT01979536 | COMPLETED | Anaplastic Large Cell Lymphoma, ALK-Positive; Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma; Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma; Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma |
National Cancer Institute (NCI) |
2013-11-13 | PHASE2 |
| NCT02584634 | TERMINATED | Non-Small Cell Lung Cancer |
Pfizer |
2015-12-18 | PHASE1; PHASE2 |
| NCT03874273 | UNKNOWN | Inflammatory Myofibroblastic Tumor |
Federal Research Institute of Pediatric Hematology, Oncology and Immunology |
2019-02-01 | PHASE2; PHASE3 |
| NCT01531361 | COMPLETED | Advanced Malignant Neoplasm; BRAF Gene Mutation; Metastatic Malignant Neoplasm; Recurrent Malignant Neoplasm; Refractory Malignant Neoplasm |
M.D. Anderson Cancer Center |
2012-02-06 | PHASE1 |
| NCT03088930 | COMPLETED | Lung Cancer, Nonsmall Cell |
University of Colorado, Denver |
2017-12-13 | PHASE2 |
| NCT01579994 | COMPLETED | Advanced Lung Cancer |
Memorial Sloan Kettering Cancer Center |
2012-04-16 | PHASE1 |
| NCT04641754 | UNKNOWN | Non-small Cell Lung Cancer |
Qilu Pharmaceutical Co., Ltd. |
2019-03-07 | PHASE2 |
| NCT02270034 | COMPLETED | Glioblastoma Multiforme (Grade IV) of Cerebellum |
Grupo Español de Investigación en Neurooncología |
2014-08-13 | PHASE1 |
| NCT02737501 | COMPLETED | Non-small Cell Lung Cancer; Lung Cancer; Advanced Malignancies; Carcinoma |
Ariad Pharmaceuticals |
2016-05-26 | PHASE3 |
| NCT02574078 | COMPLETED | Non-Small Cell Lung Cancer |
Bristol-Myers Squibb |
2015-11-23 | PHASE1; PHASE2 |
| NCT03052608 | ACTIVE_NOT_RECRUITING | Carcinoma, Non-Small-Cell Lung |
Pfizer |
2017-04-27 | PHASE3 |
| NCT04439266 | ACTIVE_NOT_RECRUITING | Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma |
National Cancer Institute (NCI) |
2015-08-12 | PHASE2 |
| NCT04439253 | ACTIVE_NOT_RECRUITING | Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma |
National Cancer Institute (NCI) |
2015-08-12 | PHASE2 |
| NCT03215693 | UNKNOWN | Non-Small Cell Lung Cancer |
Betta Pharmaceuticals Co., Ltd. |
2017-09-28 | PHASE2 |
| NCT03707847 | UNKNOWN | ALK-Positive Anaplastic Large Cell Lymphoma |
Mingzhi Zhang |
2018-10-01 | PHASE4 |
| NCT02836847 | UNKNOWN | Cholangiocarcinoma of the Extrahepatic Bile Duct; Gallbladder Cancer |
Shanghai Jiao Tong University School of Medicine |
2016-07 | PHASE2 |
| NCT03978143 | COMPLETED | Healthy Volunteers |
Pfizer |
2019-06-12 | PHASE1 |
| NCT02612194 | TERMINATED | Urinary Bladder Neoplasms; Ureteral Neoplasms; Urethral Neoplasms |
Wake Forest University Health Sciences |
2016-09-27 | PHASE2 |
| NCT02223819 | COMPLETED | Uveal Melanoma |
Columbia University |
2015-03 | PHASE2 |
| NCT04148066 | Completed | Carcinoma Non-Small-Cell Lung |
The Netherlands Cancer Institute|Roche Pharma AG |
2019-07-17 | Not Applicable |
| NCT03947385 | Recruiting | Metastatic Uveal Melanoma|Cutaneous Melanoma|Colorectal Cancer|Other Solid Tumors |
IDEAYA Biosciences |
2019-06-28 | Phase 1|Phase 2 |
| NCT02034981 | COMPLETED | Hematologic Cancers; Solid Tumors; Metastatic Cancer |
UNICANCER |
2013-08 | PHASE2 |
| NCT01744652 | COMPLETED | Advanced Cancers |
M.D. Anderson Cancer Center |
2013-03 | PHASE1 |
| NCT03672643 | Terminated | ALK or ROS1-positive NSCLC |
Pfizer |
2019-01-28 | Phase 4 |
| NCT00939770 | COMPLETED | Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Refractory Anaplastic Large Cell Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma |
Children's Oncology Group |
2009-09-21 | PHASE1; PHASE2 |
| NCT01606878 | COMPLETED | Childhood Solid Neoplasm; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Neuroblastoma |
Children's Oncology Group |
2013-04-29 | PHASE1 |
| NCT02183870 | COMPLETED | Lung Cancer; Adenocarcinoma; NSCLC |
University of Cologne |
2014-05 | PHASE2 |
| NCT01822496 | TERMINATED | Stage III Non-Small Cell Lung Cancer AJCC v7; Stage IIIA Non-Small Cell Lung Cancer AJCC v7; Stage IIIB Non-Small Cell Lung Cancer AJCC v7 |
National Cancer Institute (NCI) |
2013-11-04 | PHASE2 |
| NCT02499614 | UNKNOWN | Carcinoma, Non-Small-Cell Lung |
Fondazione Ricerca Traslazionale |
2014-12 | PHASE2 |
| NCT02838420 | COMPLETED | Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer |
Hoffmann-La Roche |
2016-08-03 | PHASE3 |
| NCT01644773 | COMPLETED | Diffuse Intrinsic Pontine Glioma; High-grade Glioma |
St. Jude Children's Research Hospital |
2012-11-27 | PHASE1 |
| NCT02207504 | COMPLETED | Castration-resistant Prostate Cancer |
Dana-Farber Cancer Institute |
2014-08 | PHASE1 |
| NCT01685138 | COMPLETED | Non-Small Cell Lung Cancer |
Novartis Pharmaceuticals |
2012-12-20 | PHASE2 |
| NCT01524926 | COMPLETED | Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma; Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor; Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1; Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma; Locally Advanced and/or Metastatic Clear Cell Sarcoma; Locally Advanced and/or Metastatic Alveolar Rhabdomyosarcoma |
European Organisation for Research and Treatment of Cancer - EORTC |
2012-09 | PHASE2 |
| NCT02511184 | TERMINATED | ALK-positive Advanced NSCLC |
Pfizer |
2015-10 | PHASE1 |
| NCT02487316 | WITHDRAWN | Systemic Anaplastic Large-Cell Lymphoma |
Jun Zhu |
2015-07 | PHASE4 |
| NCT02946359 | UNKNOWN | Lung Adenocarcinoma Metastatic |
Chinese PLA General Hospital |
2016-07 | PHASE2 |
| NCT03137134 | COMPLETED | Healthy |
Pfizer |
2017-06-20 | PHASE1 |
| NCT02040870 | COMPLETED | Non-Small Cell Lung Cancer |
Novartis Pharmaceuticals |
2014-03-07 | PHASE1; PHASE2 |
| NCT03439215 | Unknown status | Carcinoma Non-Small-Cell Lung |
Fondazione Ricerca Traslazionale|Clinical research technology Srl |
2017-06-13 | Phase 2 |
| NCT02074878 | TERMINATED | Breast Cancer |
Mothaffar Rimawi |
2014-06 | PHASE1 |
| NCT01998126 | COMPLETED | Non-small Cell Lung Cancer |
University of Utah |
2013-12-02 | PHASE1 |
| NCT01970865 | COMPLETED | ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC |
Pfizer |
2014-01-08 | PHASE1; PHASE2 |
| NCT01999972 | COMPLETED | Advanced Solid Tumors |
Pfizer |
2014-02-26 | PHASE1 |
| NCT02075840 | COMPLETED | Non-Small Cell Lung Cancer |
Hoffmann-La Roche |
2014-08-19 | PHASE3 |
| NCT02604342 | COMPLETED | Non-small Cell Lung Cancer |
Hoffmann-La Roche |
2015-11-03 | PHASE3 |
| NCT01712217 | COMPLETED | Non-small Cell Lung Cancer(NSCLC) |
Astex Pharmaceuticals, Inc. |
2012-10 | PHASE1; PHASE2 |
| NCT02134912 | TERMINATED | Adenocarcinoma of the Lung; Large Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer |
SWOG Cancer Research Network |
2014-08 | PHASE2 |
| NCT01576406 | COMPLETED | Advanced Cancer |
Pfizer |
2012-07 | PHASE1 |
| NCT01500824 | WITHDRAWN | Non-Small Cell Lung Cancer |
Pfizer |
2014-05 | PHASE2 |
| NCT01685060 | COMPLETED | Non-Small Cell Lung Cancer |
Novartis Pharmaceuticals |
2012-11-26 | PHASE2 |
| NCT02094573 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Ariad Pharmaceuticals |
2014-06-04 | PHASE2 |
| NCT01828112 | COMPLETED | Non-Small Cell Lung Cancer |
Novartis Pharmaceuticals |
2013-06-28 | PHASE3 |
| NCT02435108 | COMPLETED | c-MET Positive Gastric Cancer |
Samsung Medical Center |
2014-05-15 | PHASE2 |
| NCT01945021 | COMPLETED | Non Small Cell Lung Cancer; ROS1 Proto Oncogene; Crizotinib |
Pfizer |
2013-09-30 | PHASE2 |
| NCT01639001 | COMPLETED | NSCLC (Non-small Cell Lung Cancer) |
Pfizer |
2012-09-29 | PHASE3 |
| NCT01801111 | COMPLETED | Non-Small-Cell Lung Carcinoma |
Hoffmann-La Roche |
2013-06-20 | PHASE1; PHASE2 |
| NCT01871805 | COMPLETED | Non-Small Cell Lung Cancer |
Hoffmann-La Roche |
2013-09-30 | PHASE1; PHASE2 |
| NCT02006277 | COMPLETED | Healthy |
Pfizer |
2013-12 | PHASE1 |
| NCT01154140 | COMPLETED | Non Squamous Lung Cancer |
Pfizer |
2011-01-13 | PHASE3 |
| NCT01441388 | WITHDRAWN | Carcinoma, Renal Cell; Glioblastoma; Carcinoma, Hepatocellular |
Pfizer |
2011-12 | PHASE1 |
| NCT01419041 | COMPLETED | Renal Impairment |
Pfizer |
2011-11 | PHASE1 |
| NCT01549574 | COMPLETED | Healthy |
Pfizer |
2012-05 | PHASE1 |
| NCT01297595 | COMPLETED | Healthy |
Pfizer |
2011-03 | PHASE1 |
| NCT01154218 | COMPLETED | Healthy |
Pfizer |
2010-08 | PHASE1 |
| NCT01147055 | COMPLETED | Healthy |
Pfizer |
2010-07 | PHASE1 |
| NCT01149785 | COMPLETED | Healthy |
Pfizer |
2010-07 | PHASE1 |
| NCT01168934 | COMPLETED | Healthy |
Pfizer |
2010-08 | PHASE1 |
| NCT01125904 | COMPLETED | Healthy |
Pfizer |
2010-06 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2023-02-21)
Check the
PF-02341066 (Crizotinib)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- PF-02341066 (Crizotinib) Mechanism of Action: ALK Inhibition in Lung Adenocarcinoma Cell Research
- PF-02341066 (Crizotinib) Working Concentration | Cell Culture | Treatment
- PF-02341066 (Crizotinib) Solubility in DMSO
- PF-02341066 (Crizotinib) Stock Solution
- PF-02341066 (Crizotinib) Storage
- PF-02341066 (Crizotinib) Stability
- PF-02341066 (Crizotinib) Combination Database
- PF-02341066 (Crizotinib) Molecular Weight
- PF-02341066 (Crizotinib) SMILES
- PF-02341066 (Crizotinib) CAS Number
- PF-02341066 (Crizotinib) Chemical Structure (2D and 3D)
- PF-02341066 (Crizotinib) IC50 for Cell-based and Cell-free Assays
- PF-02341066 (Crizotinib) Sigma (PZ0191)? Try a better option.
- PF-02341066 (Crizotinib) MedChemExpress (HY-50878)? Try a better option.
- PF-02341066 (Crizotinib) Cayman (12087)? Try a better option.
- PF-02341066 (Crizotinib) APExBIO (A3020)? Try a better option.
- PF-02341066 (Crizotinib) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.